- Shuttle Pharmaceuticals (SHPH, Financial) to present at the Planet MicroCap Showcase: VEGAS 2025.
- Dr. Anatoly Dritschilo will update on the ongoing Phase 2 trial for glioblastoma and advancements in prostate cancer diagnostics.
- The presentation will occur at the Paris Hotel & Casino in Las Vegas on April 23, 2025, with webcast options available.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 2:30 PM Pacific Time. The event will be held at the Paris Hotel & Casino in Las Vegas, with options for both in-person and webcast attendance.
Dr. Anatoly Dritschilo, Chairman and Chief Scientific Officer of Shuttle Pharma, will lead the presentation. Key updates will include the company's ongoing Phase 2 trial of Ropidoxuridine in combination with radiation therapy for treating glioblastoma.
In addition to glioblastoma trials, Dr. Dritschilo will discuss developments at Shuttle Diagnostics subsidiary. This includes the advancement of pretreatment diagnostic blood tests and imaging agents specifically designed for prostate cancer patients.
Shuttle Pharmaceuticals, founded in 2012, focuses on enhancing radiation therapy outcomes by developing radiation sensitizers. These efforts aim to increase cure rates and improve survival rates for cancer patients, further cementing its role in advancing cancer treatment solutions.
